On the other hand, the CML+apoA-I+CIGB-258 group showed the highest survivability, ~92% and ~85% at 1 h and 3 h post-injection (Figure 8B), indicating synergistic anti-inflammatory activity to maximize the survivability between apoA-I and CIGB-258. Here, APOA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.